Table 3. Analysis of factors associated with fibrosis regression in F≥3 patients.
| Regression | No regression | Uni | p-value1 | Multi | p-value2 | |
|---|---|---|---|---|---|---|
| N | 169 | 140 | ||||
| ETV+ALHX group | 124 (73.4) | 87 (62.1) | 4.46 | 0.035 | 1.94 (1.12, 3.37) | 0.018 |
| Age (years) | 41.12±10.51 | 42.34±10.72 | −1.00 | 0.316 | ||
| <40, n (%) | 79 (46.7) | 58 (41.4) | 0.88 | 0.349 | ||
| Male sex, n (%) | 121 (71.6) | 102 (72.9) | 0.06 | 0.81 | ||
| Family history of HBV infection, n (%) | 81/167 (48.5) | 72 (51.4) | 0.26 | 0.610 | ||
| Family history of HCC, n (%) | 13/168 (7.7) | 24 (17.1) | 6.39 | 0.011 | 0.41 (0.18, 0.92) | 0.031 |
| History of drinking, n (%) | 5 (3.0) | 4 (2.9) | 0.00 | 0.958 | ||
| HBsAg positive duration, year | 11 (4, 20) | 10 (2, 20) | −0.26 | 0.794 | ||
| BMI (kg/m2) | 23.98±3.43,23.62 | 24.22±3.04,24.22 | −0.64 | 0.524 | ||
| WBC (×109/L) | 5.47±1.58,5.30 | 5.32±1.56,5.18 | 0.77 | 0.443 | ||
| LY% | 34.93±7.84,34.6 | 34.83±9.61,35.9 | 0.11 | 0.918 | ||
| HGB (g/L) | 143.91±17.38,147 | 146.22±16.76,148 | −1.19 | 0.237 | ||
| PLT (×109/L) | 157.57±52.26,155.00 | 144.86±46.07,143.00 | 2.25 | 0.026 | 1.00 (1.00, 1.01) | 0.012 |
| ALT (U/L) | 56.00 (38.00, 101.28) | 56.00 (35.00, 101.28) | 1.16 | 0.265 | ||
| AST (U/L) | 41.00 (28.00, 70.00) | 41.00 (30.09, 69.26) | 1.11 | 0.239 | ||
| ALP (U/L) | 87.15 (71.05, 109.22) | 89.32 (71.28, 114.91) | −0.11 | 0.914 | ||
| GGT (U/L) | 46.00 (28.50, 80.00) | 42.78 (24.91, 83.81) | −0.16 | 0.870 | ||
| ALB (g/L) | 42.46±4.91,43.00 | 41.68±4.81,42.00 | 1.41 | 0.161 | 0.943 | |
| TBil (μmol/L) | 14.70 (11.40, 20.80) | 15.90 (11.45, 20.30) | 1.27 | 0.177 | 0.217 | |
| DBil (μmol/L) | 4.70 (3.21, 7.50) | 4.70 (3.40, 7.65) | 1.71 | 0.065 | 0.077 | |
| Cr (μmol/L) | 66.97±14.13,66.00 | 65.81±12.93,65.40 | 0.75 | 0.457 | ||
| TCHO (mmol/L) | 4.42±0.93,4.31 | 4.23±0.74,4.20 | 1.85 | 0.060 | 0.688 | |
| TG (mmol/L) | 1.19±0.64,1.01 | 1.08±0.50,1.02 | 1.59 | 0.113 | 0.798 | |
| AFP (ng/mL) | 4.53 (2.94, 12.98) | 5.00 (3.10, 16.45) | −0.08 | 0.940 | ||
| INR | 1.10±0.11,1.08 | 1.11±0.15,1.10 | −1.43 | 0.154 | 0.10 (0.01, 0.87) | 0.037 |
| HBV DNA (log10 IU/mL) | 5.62±1.90,5.68 | 5.62±1.75,5.83 | −0.26 | 0.797 | ||
| HBsAg (log10 IU/mL) | 3.32±0.69,3.38 | 3.22±0.66,3.31 | 1.32 | 0.189 | 0.092 | |
| HBeAg (+), n (%) | 93/167 (55.7) | 80/136 (58.8) | 0.30 | 0.583 | ||
| qAnti-HBc (log10 IU/mL) | 3.88±0.69,3.90 | 3.81±0.83,3.82 | 0.75 | 0.448 | ||
| LSM (kPa) | 11.90 (8.50, 18.55) | 13.45 (8.90, 19.90) | −0.64 | 0.520 | ||
| HAI | 2.42 | 0.490 | ||||
| ≤4, n (%) | 38 (22.5) | 42 (30.0) | ||||
| 5–6, n (%) | 53 (31.4) | 39 (27.9) | ||||
| 7–9, n (%) | 49 (29.0) | 39 (27.9) | ||||
| ≥10, n (%) | 29 (17.2) | 20 (14.3) | ||||
| F | 30.67 | 0.000 | 2.49 (1.81, 3.42) | 0.000 | ||
| 3–4 | 99 (58.6) | 122 (87.1) | ||||
| 5–6 | 70 (41.4) | 18 (12.9) |
ALHX, An-Luo-Hua-Xian; ETV, Entecavir; F, liver histologic fibrosis score; HAI, liver histologic activity scores of inflammatory; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; BMI, body mass index; Cr, creatinine.